Meridian Bioscience, Inc. Gets Australian Approval for Molecular Group B Strep Test

Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received Australian regulatory clearance of a molecular test for group B streptococcus. The test is part of Cincinnati-area Meridian’s illumigene line of molecular diagnostic tests. The illumigene product line is key to Meridian’s future as more customers look to molecular diagnostics, a means of analyzing the makeup of an organism at the genetic level. Meridian received U.S. Food and Drug Administration clearance of the test in December.